December 29, 2020Open Access

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

MMMiguel MartínHospital General Universitario Gregorio Marañón CZChristoph ZielinskiTufts University MRManuel Ruíz‐BorregoHospital Universitario Virgen del Rocío

Key Points

Key points are not available for this paper at this time.

Abstract

There was no statistical superiority of palbociclib plus ET over capecitabine with respect to PFS in MBC patients resistant to AIs. Palbociclib plus ET showed a better safety profile and improved quality of life.

AIに質問

Bookmark

View Full Paper